[ { "asset": "abrocitinib", "nct_id": "NCT06807268", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-05-02", "conditions": "Eczema", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "abrocitinib", "nct_id": "NCT06807281", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-02-22", "conditions": "Atopic Dermatitis", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "acasunlimab", "nct_id": "NCT06635824", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-30", "conditions": "PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "alectinib", "nct_id": "NCT03178552", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-31", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "alectinib", "nct_id": "NCT03768063", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-07-05", "conditions": "Cancer", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "alectinib", "nct_id": "NCT05170204", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2030-06-16", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "alectinib", "nct_id": "NCT05722886", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2029-10", "conditions": "Haematological Malignancy; Solid Tumour", "arm_role": "experimental", "sponsor_raw": "Cancer Research UK", "company_name": null, "ticker": null }, { "asset": "alectinib", "nct_id": "NCT05770037", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2029-10", "conditions": "Haematological Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Anaplastic Large Cell Lymphoma; Lymphoma; Renal Cell Carcinoma; Neuroblastoma; Solid Tumour", "arm_role": "experimental", "sponsor_raw": "Cancer Research UK", "company_name": null, "ticker": null }, { "asset": "alectinib", "nct_id": "NCT06765109", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-12", "conditions": "Non-small Cell Lung Cancer; Anaplastic Lymphoma Kinase-positive", "arm_role": "active_comparator", "sponsor_raw": "Nuvalent Inc.", "company_name": "Nuvalent, Inc.", "ticker": "NUVL" }, { "asset": "anifrolumab", "nct_id": "NCT04877691", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-08-22", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "anifrolumab", "nct_id": "NCT05138133", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-02-26", "conditions": "Lupus Nephritis", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "anifrolumab", "nct_id": "NCT05835310", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-10-05", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "anifrolumab", "nct_id": "NCT07430306", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-01-26", "conditions": "Systemic Lupus Erythematosus", "arm_role": "other", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "anifrolumab", "nct_id": "NCT07691970", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2032-12-31", "conditions": "Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "axitinib", "nct_id": "NCT05059522", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-31", "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "axitinib", "nct_id": "NCT06364631", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-05-05", "conditions": "Metastatic Kidney Cancer; Metastatic Kidney Carcinoma", "arm_role": "other", "sponsor_raw": "Gustave Roussy, Cancer Campus, Grand Paris", "company_name": null, "ticker": null }, { "asset": "belzutifan", "nct_id": "NCT04195750", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-04-15", "conditions": "Carcinoma, Renal Cell", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT04586231", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-02-02", "conditions": "Carcinoma, Renal Cell", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT04736706", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-29", "conditions": "Carcinoma, Renal Cell", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT05239728", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-28", "conditions": "Carcinoma, Renal Cell", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT05899049", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-06-07", "conditions": "Carcinoma, Renal Cell", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT07227402", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-02-27", "conditions": "Renal Cell Carcinoma", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT07405164", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2034-01-14", "conditions": "Von Hippel-Lindau Disease; Malignant Neoplasms", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "belzutifan", "nct_id": "NCT07489495", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-11-27", "conditions": "Carcinoma, Renal Cell", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "binimetinib", "nct_id": "NCT04657991", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-01-12", "conditions": "Melanoma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "binimetinib", "nct_id": "NCT05615818", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Biliary Tract Neoplasms", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "cagrilintide", "nct_id": "NCT05567796", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-10-30", "conditions": "Obesity", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT05669755", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09-01", "conditions": "Cardiovascular Disease", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT06780449", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-08-28", "conditions": "Obesity", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT07011667", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03-01", "conditions": "Obesity", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT07220642", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-05-11", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT07220759", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-05-12", "conditions": "Overweight; Obesity; Type 2 Diabetes", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT07253285", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-03-20", "conditions": "Overweight; Obesity", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT07282613", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2029-09-07", "conditions": "Diabetes Mellitus, Type 2", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "cagrilintide", "nct_id": "NCT07564414", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-02-23", "conditions": "Obesity; Type 2 Diabetes", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "camizestrant", "nct_id": "NCT04711252", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-08-24", "conditions": "ER-Positive HER2-Negative Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "camizestrant", "nct_id": "NCT04964934", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-06-30", "conditions": "ER-Positive HER2-Negative Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "camizestrant", "nct_id": "NCT05774951", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-04-20", "conditions": "Breast Cancer, Early Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "camizestrant", "nct_id": "NCT05952557", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-03-04", "conditions": "Breast Cancer, Early Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "camizestrant", "nct_id": "NCT06380751", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-03-30", "conditions": "Advanced Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "camizestrant", "nct_id": "NCT07647328", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-02-28", "conditions": "ER-Positive HER2-Negative Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "cenerimod", "nct_id": "NCT05648500", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-31", "conditions": "Lupus Erythematosus, Systemic", "arm_role": "experimental", "sponsor_raw": "Viatris Innovation GmbH", "company_name": "Viatris Inc", "ticker": "VTRS" }, { "asset": "cenerimod", "nct_id": "NCT05672576", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-31", "conditions": "Lupus Erythematosus, Systemic", "arm_role": "experimental", "sponsor_raw": "Viatris Innovation GmbH", "company_name": "Viatris Inc", "ticker": "VTRS" }, { "asset": "cenerimod", "nct_id": "NCT06475742", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2028-05", "conditions": "Lupus Erythematosus, Systemic", "arm_role": "experimental", "sponsor_raw": "Viatris Innovation GmbH", "company_name": "Viatris Inc", "ticker": "VTRS" }, { "asset": "cenerimod", "nct_id": "NCT07201129", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-08", "conditions": "Nephritis, Lupus; Lupus Erythematosus, Systemic", "arm_role": "experimental", "sponsor_raw": "Viatris Innovation GmbH", "company_name": "Viatris Inc", "ticker": "VTRS" }, { "asset": "cretostimogene grenadenorepvec", "nct_id": "NCT04452591", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2030-06-16", "conditions": "Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer", "arm_role": "experimental", "sponsor_raw": "CG Oncology, Inc.", "company_name": "CG Oncology, Inc.", "ticker": "CGON" }, { "asset": "cretostimogene grenadenorepvec", "nct_id": "NCT06111235", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11", "conditions": "Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma", "arm_role": "experimental", "sponsor_raw": "CG Oncology, Inc.", "company_name": "CG Oncology, Inc.", "ticker": "CGON" }, { "asset": "dapagliflozin", "nct_id": "NCT05374291", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2027-07", "conditions": "Kidney Disease, Chronic; Renal Transplant Failure; Heart Failure; Kidney Failure; Death", "arm_role": "experimental", "sponsor_raw": "University Medical Center Groningen", "company_name": null, "ticker": null }, { "asset": "dapagliflozin", "nct_id": "NCT05886088", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2026-05", "conditions": "Type 2 Diabetes Mellitus", "arm_role": "active_comparator", "sponsor_raw": "EMS", "company_name": null, "ticker": null }, { "asset": "dapagliflozin", "nct_id": "NCT07082114", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-02-16", "conditions": "Type 2 Diabetes", "arm_role": "active_comparator", "sponsor_raw": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "dapagliflozin", "nct_id": "NCT07662044", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-07-14", "conditions": "Type 2 Diabetes Mellitus", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "dapagliflozin", "nct_id": "NCT07662109", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-07-05", "conditions": "Type 2 Diabetes Mellitus", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "darolutamide", "nct_id": "NCT03903835", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12", "conditions": "Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)", "arm_role": "experimental", "sponsor_raw": "Karolinska Institutet", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT04136353", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-01-31", "conditions": "Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "University of Sydney", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT04464226", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-06-26", "conditions": "Cancer", "arm_role": "experimental", "sponsor_raw": "Bayer", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT04916613", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-03", "conditions": "Prostate Cancer Metastatic", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT05116475", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-02", "conditions": "Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT05794906", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-30", "conditions": "Biochemically Recurrent Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "Bayer", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT06120491", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09-30", "conditions": "Metastatic Castration-Sensitive Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "darolutamide", "nct_id": "NCT06276465", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-10-15", "conditions": "Prostatic Cancer, Castration-Resistant", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT06282588", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2030-07-31", "conditions": "Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "Cancer Research Antwerp", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT06625970", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2033-10", "conditions": "High Risk Prostate Carcinoma; Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "darolutamide", "nct_id": "NCT07611110", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-02-13", "conditions": "Metastatic Castration-resistant Prostate Cancer", "arm_role": "active_comparator", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "darolutamide", "nct_id": "NCT07711002", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2031-06-17", "conditions": "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "darovasertib", "nct_id": "NCT05987332", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-15", "conditions": "Metastatic Uveal Melanoma", "arm_role": "experimental", "sponsor_raw": "IDEAYA Biosciences", "company_name": "IDEAYA Biosciences, Inc.", "ticker": "IDYA" }, { "asset": "darovasertib", "nct_id": "NCT07015190", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-10", "conditions": "Uveal Melanoma", "arm_role": "experimental", "sponsor_raw": "IDEAYA Biosciences", "company_name": "IDEAYA Biosciences, Inc.", "ticker": "IDYA" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT04656652", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-05-10", "conditions": "Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT05104866", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-07-24", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT05215340", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2030-03-04", "conditions": "Metastatic Non Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT05374512", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-08-25", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT05555732", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-05-11", "conditions": "Metastatic Non Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT05629585", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09-20", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT05687266", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-11-01", "conditions": "NSCLC", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT06103864", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-07-28", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT06112379", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-11-20", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT06350097", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-03-21", "conditions": "Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT06357533", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-12-28", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT06417814", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-09-30", "conditions": "Metastatic Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT06564844", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-06-30", "conditions": "Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT07129993", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2029-06-01", "conditions": "Urothelial Cancer; Bladder Cancer", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT07205822", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-02-02", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "datopotamab deruxtecan", "nct_id": "NCT07291037", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-01-29", "conditions": "Non-small Cell Lung Cancer (NSCLC)", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "daunorubicin", "nct_id": "NCT03117751", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma", "arm_role": "experimental", "sponsor_raw": "St. Jude Children's Research Hospital", "company_name": null, "ticker": null }, { "asset": "daunorubicin", "nct_id": "NCT03897127", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-06", "conditions": "Acute Myeloid Leukemia", "arm_role": "active_comparator", "sponsor_raw": "University of Ulm", "company_name": null, "ticker": null }, { "asset": "daunorubicin", "nct_id": "NCT05726110", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2024-12-10", "conditions": "Relapsed or Refractory Acute Myeloid Leukemia", "arm_role": "experimental", "sponsor_raw": "Shanxi Bethune Hospital", "company_name": null, "ticker": null }, { "asset": "daunorubicin", "nct_id": "NCT07007312", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-11", "conditions": "Acute Myeloid Leukemia (AML)", "arm_role": "experimental", "sponsor_raw": "Kura Oncology, Inc.", "company_name": "Kura Oncology, Inc.", "ticker": "KURA" }, { "asset": "daunorubicin", "nct_id": "NCT07255872", "phase": "PHASE2;PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-12", "conditions": "Acute Myeloid Leukemia", "arm_role": "experimental", "sponsor_raw": "Sichuan Baili Pharmaceutical Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "deucravacitinib", "nct_id": "NCT04036435", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-25", "conditions": "Psoriasis", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT04772079", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-01-01", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT04908189", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-02-06", "conditions": "Psoriatic Arthritis", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT04908202", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-09-05", "conditions": "Psoriatic Arthritis", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT05617677", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-19", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT05620407", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-19", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT06143878", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-09-17", "conditions": "Plaque Psoriasis", "arm_role": "active_comparator", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "deucravacitinib", "nct_id": "NCT06220604", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-11-15", "conditions": "Plaque Psoriasis", "arm_role": "active_comparator", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "deucravacitinib", "nct_id": "NCT06869551", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-03-06", "conditions": "Juvenile Psoriatic Arthritis", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT06979453", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-10-12", "conditions": "Plaque Psoriasis", "arm_role": "active_comparator", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT07116967", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-01-16", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "deucravacitinib", "nct_id": "NCT07326813", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-07-12", "conditions": "Plaque Psoriasis", "arm_role": "active_comparator", "sponsor_raw": "InventisBio Co., Ltd", "company_name": null, "ticker": null }, { "asset": "deucrictibant", "nct_id": "NCT05396105", "phase": "PHASE2;PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2027-06", "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT05396105", "phase": "PHASE2;PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2027-06", "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT05396105", "phase": "PHASE2;PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2027-06", "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT05396105", "phase": "PHASE2;PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2027-06", "conditions": "Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; Hereditary Angioedema - Type 3; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema Type III; Hereditary Angioedema (HAE); Hereditary Angioedema Type I and II; HAE With Normal C1 Esterase Inhibitor", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT06669754", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-08", "conditions": "Hereditary Angioedema (HAE)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT06679881", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-12", "conditions": "Hereditary Angioedema (HAE)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deucrictibant", "nct_id": "NCT07266805", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)", "arm_role": "experimental", "sponsor_raw": "Pharvaris Netherlands B.V.", "company_name": "Pharvaris N.V.", "ticker": "PHVS" }, { "asset": "deuruxolitinib", "nct_id": "NCT03898479", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-05", "conditions": "Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Sun Pharmaceutical Industries, Inc.", "company_name": "TEVA PHARMACEUTICAL INDUSTRIES LTD", "ticker": "TEVA" }, { "asset": "deuruxolitinib", "nct_id": "NCT07133308", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-05", "conditions": "Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Sun Pharmaceutical Industries, Inc.", "company_name": "TEVA PHARMACEUTICAL INDUSTRIES LTD", "ticker": "TEVA" }, { "asset": "deuruxolitinib", "nct_id": "NCT07617597", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-02", "conditions": "Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Sun Pharma Japan Limited", "company_name": null, "ticker": null }, { "asset": "disitamab vedotin", "nct_id": "NCT05302284", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12-31", "conditions": "Urothelial Carcinoma; HER2-expressing", "arm_role": "experimental", "sponsor_raw": "RemeGen Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "disitamab vedotin", "nct_id": "NCT05911295", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-29", "conditions": "Urothelial Carcinoma", "arm_role": "experimental", "sponsor_raw": "Seagen, a wholly owned subsidiary of Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "disitamab vedotin", "nct_id": "NCT05980481", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-07-10", "conditions": "Gastric Cancer", "arm_role": "experimental", "sponsor_raw": "RemeGen Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "disitamab vedotin", "nct_id": "NCT05980481", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-07-10", "conditions": "Gastric Cancer", "arm_role": "experimental", "sponsor_raw": "RemeGen Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "disitamab vedotin", "nct_id": "NCT06221748", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2026-12", "conditions": "Gastric Cancer; Gastroesophageal Junction Adenocarcinoma", "arm_role": "experimental", "sponsor_raw": "RemeGen Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "disitamab vedotin", "nct_id": "NCT07315750", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-06-30", "conditions": "Gastric Carcinoma", "arm_role": "experimental", "sponsor_raw": "RemeGen Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "donidalorsen", "nct_id": "NCT05392114", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12", "conditions": "Hereditary Angioedema", "arm_role": "experimental", "sponsor_raw": "Ionis Pharmaceuticals, Inc.", "company_name": "IONIS PHARMACEUTICALS INC", "ticker": "IONS" }, { "asset": "donidalorsen", "nct_id": "NCT07298447", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-06", "conditions": "Hereditary Angioedema (HAE)", "arm_role": "experimental", "sponsor_raw": "Ionis Pharmaceuticals, Inc.", "company_name": "IONIS PHARMACEUTICALS INC", "ticker": "IONS" }, { "asset": "efgartigimod", "nct_id": "NCT04833894", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2027-03", "conditions": "Generalized Myasthenia Gravis", "arm_role": "experimental", "sponsor_raw": "argenx", "company_name": "ARGENX SE", "ticker": "ARGX" }, { "asset": "efgartigimod", "nct_id": "NCT06298552", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-06-30", "conditions": "Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized; Myasthenia Gravis", "arm_role": "experimental", "sponsor_raw": "argenx", "company_name": "ARGENX SE", "ticker": "ARGX" }, { "asset": "efgartigimod", "nct_id": "NCT07217587", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-09-28", "conditions": "Myasthenia Gravis", "arm_role": "active_comparator", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "eftilagimod alfa", "nct_id": "NCT06726265", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-06", "conditions": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)", "arm_role": "experimental", "sponsor_raw": "Immutep S.A.S.", "company_name": "IMMUTEP Ltd", "ticker": "IMMP" }, { "asset": "eftilagimod alpha", "nct_id": "NCT05747794", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-31", "conditions": "Breast Carcinoma", "arm_role": "experimental", "sponsor_raw": "Immutep S.A.S.", "company_name": "IMMUTEP Ltd", "ticker": "IMMP" }, { "asset": "elranatamab", "nct_id": "NCT05020236", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-04-27", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT05317416", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08-04", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT05317416", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08-04", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT05317416", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08-04", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT05317416", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08-04", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT05623020", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-10-18", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT06152575", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-08-30", "conditions": "Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "elranatamab", "nct_id": "NCT06918002", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2036-05", "conditions": "Multiple Myeloma, Newly Diagnosed", "arm_role": "experimental", "sponsor_raw": "Intergroupe Francophone du Myelome", "company_name": null, "ticker": null }, { "asset": "elranatamab", "nct_id": "NCT07647432", "phase": "PHASE2;PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2029-12-01", "conditions": "Plasmablastic Lymphoma; Hiv; Consolidation", "arm_role": "experimental", "sponsor_raw": "University of Illinois at Chicago", "company_name": null, "ticker": null }, { "asset": "encorafenib", "nct_id": "NCT04607421", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-03-01", "conditions": "Neoplasms", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "encorafenib", "nct_id": "NCT04657991", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-01-12", "conditions": "Melanoma", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "encorafenib", "nct_id": "NCT05615818", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Biliary Tract Neoplasms", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "enlicitide decanoate", "nct_id": "NCT06008756", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-11-29", "conditions": "Arteriosclerosis; Hypercholesterolaemia", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "enlicitide decanoate", "nct_id": "NCT06492291", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-10-13", "conditions": "Hypercholesterolemia", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "enlicitide decanoate", "nct_id": "NCT07058077", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2033-12-04", "conditions": "Heterozygous Familial Hypercholesterolemia (HeFH)", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "enlicitide decanoate", "nct_id": "NCT07216482", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-02", "conditions": "Hyperlipidemia", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "epcoritamab", "nct_id": "NCT04628494", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-10-13", "conditions": "Diffuse Large B-cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "epcoritamab", "nct_id": "NCT05409066", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-12", "conditions": "Follicular Lymphoma (FL)", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "epcoritamab", "nct_id": "NCT05578976", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-06", "conditions": "Diffuse Large B-Cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "epcoritamab", "nct_id": "NCT06191744", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2037-11", "conditions": "Follicular Lymphoma (FL)", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "epcoritamab", "nct_id": "NCT06508658", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-03", "conditions": "Diffuse Large B-Cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "epcoritamab", "nct_id": "NCT07226752", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-10-13", "conditions": "Diffuse Large B-Cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "erwinia asparaginase", "nct_id": "NCT03020030", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11-30", "conditions": "Acute Lymphoblastic Leukemia, Pediatric", "arm_role": "experimental", "sponsor_raw": "Dana-Farber Cancer Institute", "company_name": "DANA Inc", "ticker": "DAN" }, { "asset": "erwinia asparaginase", "nct_id": "NCT03117751", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma", "arm_role": "experimental", "sponsor_raw": "St. Jude Children's Research Hospital", "company_name": null, "ticker": null }, { "asset": "fianlimab", "nct_id": "NCT05352672", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-03-12", "conditions": "Melanoma", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "fianlimab", "nct_id": "NCT05608291", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-27", "conditions": "Melanoma", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "fianlimab", "nct_id": "NCT05785767", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09-28", "conditions": "Advanced Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "fianlimab", "nct_id": "NCT05800015", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2030-01-16", "conditions": "Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "fianlimab", "nct_id": "NCT06246916", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-03-22", "conditions": "Melanoma", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "golcadomide", "nct_id": "NCT06356129", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08-09", "conditions": "Large B-cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Celgene", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "golcadomide", "nct_id": "NCT06911502", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-04-24", "conditions": "Follicular Lymphoma", "arm_role": "experimental", "sponsor_raw": "Celgene", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "ianalumab", "nct_id": "NCT05624749", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-04-12", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "ianalumab", "nct_id": "NCT05639114", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03-24", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "ianalumab", "nct_id": "NCT06133972", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-04-08", "conditions": "Systemic Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "ianalumab", "nct_id": "NCT06711887", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2035-08-01", "conditions": "Lupus Nephritis", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "ibrutinib", "nct_id": "NCT01804686", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12-31", "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Waldenstrom Macroglobulinemia; Chronic Graft Versus Host Disease", "arm_role": "experimental", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT02477696", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2020-09-15", "conditions": "Chronic Lymphocytic Leukemia", "arm_role": "active_comparator", "sponsor_raw": "Acerta Pharma BV", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT03462719", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2021-02-26", "conditions": "Leukemia, Lymphocytic, Chronic, B-Cell", "arm_role": "experimental", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT03462719", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2021-02-26", "conditions": "Leukemia, Lymphocytic, Chronic, B-Cell", "arm_role": "experimental", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT04212013", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03-18", "conditions": "Marginal Zone Lymphoma", "arm_role": "experimental", "sponsor_raw": "Memorial Sloan Kettering Cancer Center", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT04608318", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09", "conditions": "Chronic Lymphoid Leukemia", "arm_role": "experimental", "sponsor_raw": "German CLL Study Group", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT04662255", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01", "conditions": "Lymphoma, Mantle-Cell", "arm_role": "active_comparator", "sponsor_raw": "Loxo Oncology, Inc.", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT05254743", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-10", "conditions": "Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma", "arm_role": "active_comparator", "sponsor_raw": "Loxo Oncology, Inc.", "company_name": null, "ticker": null }, { "asset": "ibrutinib", "nct_id": "NCT06136559", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-09-07", "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma", "arm_role": "active_comparator", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "ibrutinib", "nct_id": "NCT07377578", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-05-30", "conditions": "Mantle Cell Lymphoma", "arm_role": "active_comparator", "sponsor_raw": "Guangzhou Lupeng Pharmaceutical Company LTD.", "company_name": null, "ticker": null }, { "asset": "ifinatamab deruxtecan", "nct_id": "NCT06203210", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-04-30", "conditions": "Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "ifinatamab deruxtecan", "nct_id": "NCT06644781", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-06-01", "conditions": "Esophageal Squamous Cell Carcinoma", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "ifinatamab deruxtecan", "nct_id": "NCT06925737", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-06-26", "conditions": "Prostate Cancer; Prostatic Neoplasms", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "inclisiran", "nct_id": "NCT03705234", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10", "conditions": "Atherosclerotic Cardiovascular Disease", "arm_role": "experimental", "sponsor_raw": "University of Oxford", "company_name": null, "ticker": null }, { "asset": "inclisiran", "nct_id": "NCT04765657", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2022-06-09", "conditions": "Hypercholesterolemia", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT05030428", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-10-13", "conditions": "Atherosclerotic Cardiovascular Disease", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT05360446", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-26", "conditions": "Coronary Artery Disease", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT05682378", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-03-25", "conditions": "Heterozygous or Homozygous Familial Hypercholesterolemia", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT06597006", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-03-23", "conditions": "Familial Hypercholesterolemia - Homozygous", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT06597019", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-03-21", "conditions": "Familial Hypercholesterolemia - Heterozygous", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT06813911", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-02-03", "conditions": "Atherosclerotic Cardiovascular Disease (ASCVD)", "arm_role": "active_comparator", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "inclisiran", "nct_id": "NCT07102628", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-02-11", "conditions": "Acute Coronary Syndrome", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "iptacopan", "nct_id": "NCT06517758", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-04-30", "conditions": "Generalized Myasthenia Gravis", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "ivonescimab", "nct_id": "NCT05184712", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2023-03-10", "conditions": "Non-Squamous Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Akeso", "company_name": null, "ticker": null }, { "asset": "ivonescimab", "nct_id": "NCT05499390", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-01-29", "conditions": "Advanced Non-small-cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Akeso", "company_name": null, "ticker": null }, { "asset": "ivonescimab", "nct_id": "NCT05899608", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-12-31", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Summit Therapeutics", "company_name": "Summit Therapeutics Inc.", "ticker": "SMMT" }, { "asset": "ivonescimab", "nct_id": "NCT06396065", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-04-12", "conditions": "Non-Squamous Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Summit Therapeutics", "company_name": "Summit Therapeutics Inc.", "ticker": "SMMT" }, { "asset": "ivonescimab", "nct_id": "NCT06767514", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-04", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Summit Therapeutics", "company_name": "Summit Therapeutics Inc.", "ticker": "SMMT" }, { "asset": "ivonescimab", "nct_id": "NCT06767527", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12", "conditions": "Triple-Negative Breast Cancer (TNBC)", "arm_role": "experimental", "sponsor_raw": "Akeso", "company_name": null, "ticker": null }, { "asset": "ivonescimab", "nct_id": "NCT06951503", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-01-13", "conditions": "Colorectal Adenocarcinoma", "arm_role": "experimental", "sponsor_raw": "Akeso", "company_name": null, "ticker": null }, { "asset": "ivonescimab", "nct_id": "NCT07010263", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-12-31", "conditions": "Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Akeso", "company_name": null, "ticker": null }, { "asset": "ivonescimab", "nct_id": "NCT07228832", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-05-31", "conditions": "Metastatic Colorectal Cancer (CRC)", "arm_role": "experimental", "sponsor_raw": "Summit Therapeutics", "company_name": "Summit Therapeutics Inc.", "ticker": "SMMT" }, { "asset": "laroprovstat", "nct_id": "NCT06834932", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-02-22", "conditions": "Dyslipidaemia", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "laroprovstat", "nct_id": "NCT07000123", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-11", "conditions": "Cardiovascular Disease", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "laroprovstat", "nct_id": "NCT07000136", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-04", "conditions": "Heterozygous Familial Hypercholesterolaemia", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "laroprovstat", "nct_id": "NCT07000357", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-10-26", "conditions": "Cardiovascular Disease", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "laroprovstat", "nct_id": "NCT07619131", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-07-30", "conditions": "Hypercholesterolaemia", "arm_role": "active_comparator", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "lebrikizumab", "nct_id": "NCT05559359", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-01-14", "conditions": "Atopic Dermatitis; Eczema", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "lebrikizumab", "nct_id": "NCT05735483", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2027-12", "conditions": "Atopic Dermatitis; Eczema", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "lebrikizumab", "nct_id": "NCT06280716", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-09-25", "conditions": "Atopic Dermatitis", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "lebrikizumab", "nct_id": "NCT06526182", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-04-25", "conditions": "Dermatitis, Atopic; Eczema", "arm_role": "experimental", "sponsor_raw": "Almirall, S.A.", "company_name": null, "ticker": null }, { "asset": "lebrikizumab", "nct_id": "NCT07542483", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2028-08", "conditions": "Nummular Eczema", "arm_role": "experimental", "sponsor_raw": "Almirall, S.A.", "company_name": null, "ticker": null }, { "asset": "lerotinib", "nct_id": "NCT04415853", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-08", "conditions": "Esophageal Cancer", "arm_role": "experimental", "sponsor_raw": "Sunshine Lake Pharma Co., Ltd.", "company_name": "Sunshine Biopharma Inc.", "ticker": "SBFM" }, { "asset": "lisaftoclax", "nct_id": "NCT06319456", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-08", "conditions": "CLL/SLL", "arm_role": "experimental", "sponsor_raw": "Ascentage Pharma Group Inc.", "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL", "ticker": "AAPG" }, { "asset": "lisaftoclax", "nct_id": "NCT06389292", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-05-25", "conditions": "Acute Myeloid Leukemia", "arm_role": "experimental", "sponsor_raw": "Ascentage Pharma Group Inc.", "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL", "ticker": "AAPG" }, { "asset": "litifilimab", "nct_id": "NCT04895241", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Lupus Erythematosus, Systemic", "arm_role": "experimental", "sponsor_raw": "Biogen", "company_name": "BIOGEN INC.", "ticker": "BIIB" }, { "asset": "litifilimab", "nct_id": "NCT04961567", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-27", "conditions": "Lupus Erythematosus, Systemic", "arm_role": "experimental", "sponsor_raw": "Biogen", "company_name": "BIOGEN INC.", "ticker": "BIIB" }, { "asset": "litifilimab", "nct_id": "NCT05352919", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2030-03-29", "conditions": "Systemic Lupus Erythematosus (SLE)", "arm_role": "experimental", "sponsor_raw": "Biogen", "company_name": "BIOGEN INC.", "ticker": "BIIB" }, { "asset": "litifilimab", "nct_id": "NCT05531565", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10-20", "conditions": "Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Biogen", "company_name": "BIOGEN INC.", "ticker": "BIIB" }, { "asset": "litifilimab", "nct_id": "NCT06044337", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2029-06-26", "conditions": "Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus", "arm_role": "experimental", "sponsor_raw": "Biogen", "company_name": "BIOGEN INC.", "ticker": "BIIB" }, { "asset": "lorlatanib", "nct_id": "NCT05059522", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-31", "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "lutikizumab", "nct_id": "NCT06468228", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12", "conditions": "Hidradenitis Suppurativa", "arm_role": "experimental", "sponsor_raw": "AbbVie", "company_name": "AbbVie Inc.", "ticker": "ABBV" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT06858839", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-21", "conditions": "Obesity", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT06858878", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-21", "conditions": "Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT06987695", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-04-27", "conditions": "Obesity Disease", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07037433", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-06-30", "conditions": "Atherosclerotic Cardiovascular Disease; Overweight; Obesity", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07037459", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-06-30", "conditions": "Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07225686", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-09-29", "conditions": "Obesity; Obstructive Sleep Apnea", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07226765", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-09-29", "conditions": "Obstructive Sleep Apnea", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07575399", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-01-03", "conditions": "Obesity or Overweight", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07684144", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-12-26", "conditions": "Obesity; Overweight; Diabetes Mellitus, Type 2", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "maridebart cafraglutide", "nct_id": "NCT07684235", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-12-26", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "mercaptopurine", "nct_id": "NCT03020030", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11-30", "conditions": "Acute Lymphoblastic Leukemia, Pediatric", "arm_role": "other", "sponsor_raw": "Dana-Farber Cancer Institute", "company_name": "DANA Inc", "ticker": "DAN" }, { "asset": "mercaptopurine", "nct_id": "NCT03117751", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma", "arm_role": "experimental", "sponsor_raw": "St. Jude Children's Research Hospital", "company_name": null, "ticker": null }, { "asset": "mevrometostat", "nct_id": "NCT06551324", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-13", "conditions": "Metastatic Castrate Resistant Prostate Cancer (mCRPC)", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "mevrometostat", "nct_id": "NCT06629779", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12-02", "conditions": "Metastatic Castration-Resistant Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "mevrometostat", "nct_id": "NCT07028853", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-09-12", "conditions": "Metastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "mezigdomide", "nct_id": "NCT05519085", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-01-10", "conditions": "Relapsed or Refractory Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Celgene", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "mezigdomide", "nct_id": "NCT05552976", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-18", "conditions": "Relapsed or Refractory Multiple Myeloma", "arm_role": "experimental", "sponsor_raw": "Bristol-Myers Squibb", "company_name": "BRISTOL MYERS SQUIBB CO", "ticker": "BMY" }, { "asset": "mibavademab", "nct_id": "NCT06548100", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-14", "conditions": "Generalized Lipodystrophy", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "mibavademab", "nct_id": "NCT07220772", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06-18", "conditions": "Monogenic Obesity", "arm_role": "experimental", "sponsor_raw": "Regeneron Pharmaceuticals", "company_name": "REGENERON PHARMACEUTICALS, INC.", "ticker": "REGN" }, { "asset": "midazolam", "nct_id": "NCT05208047", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2025-09-30", "conditions": "Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer", "arm_role": "experimental", "sponsor_raw": "Cogent Biosciences, Inc.", "company_name": "Cogent Biosciences, Inc.", "ticker": "COGT" }, { "asset": "midazolam", "nct_id": "NCT05646862", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11-13", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "migalastat", "nct_id": "NCT04020055", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-31", "conditions": "Fabry Disease", "arm_role": "experimental", "sponsor_raw": "Amicus Therapeutics", "company_name": null, "ticker": null }, { "asset": "migalastat", "nct_id": "NCT05280548", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-05-22", "conditions": "Fabry Disease", "arm_role": "active_comparator", "sponsor_raw": "Sanofi", "company_name": "Sanofi", "ticker": "SNY" }, { "asset": "migalastat", "nct_id": "NCT06904261", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-12", "conditions": "Fabry Disease", "arm_role": "experimental", "sponsor_raw": "Amicus Therapeutics", "company_name": null, "ticker": null }, { "asset": "minoxidil", "nct_id": "NCT05888922", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-10", "conditions": "Androgenetic Alopecia; Female Pattern Baldness", "arm_role": "experimental", "sponsor_raw": "Industrial Farmacéutica Cantabria, S.A.", "company_name": null, "ticker": null }, { "asset": "minoxidil", "nct_id": "NCT05888922", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-10", "conditions": "Androgenetic Alopecia; Female Pattern Baldness", "arm_role": "active_comparator", "sponsor_raw": "Industrial Farmacéutica Cantabria, S.A.", "company_name": null, "ticker": null }, { "asset": "minoxidil", "nct_id": "NCT06501924", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2025-10-17", "conditions": "Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness", "arm_role": "active_comparator", "sponsor_raw": "Applied Biology, Inc.", "company_name": null, "ticker": null }, { "asset": "minoxidil", "nct_id": "NCT07080931", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-12", "conditions": "Androgenetic Alopecia", "arm_role": "experimental", "sponsor_raw": "Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.", "company_name": "Sunshine Biopharma Inc.", "ticker": "SBFM" }, { "asset": "minoxidil", "nct_id": "NCT07435012", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-12", "conditions": "Androgenic Alopecia", "arm_role": "active_comparator", "sponsor_raw": "Triple Hair Inc", "company_name": null, "ticker": null }, { "asset": "minoxidil", "nct_id": "NCT07529977", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2028-10-30", "conditions": "Androgenetic Alopecia; Androgenetic Alopecia (AGA)", "arm_role": "experimental", "sponsor_raw": "Eurofarma Laboratorios S.A.", "company_name": null, "ticker": null }, { "asset": "monalizumab", "nct_id": "NCT04590963", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2022-05-11", "conditions": "Squamous Cell Carcinoma of the Head and Neck", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "monalizumab", "nct_id": "NCT05221840", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "nelarabine", "nct_id": "NCT03020030", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11-30", "conditions": "Acute Lymphoblastic Leukemia, Pediatric", "arm_role": "other", "sponsor_raw": "Dana-Farber Cancer Institute", "company_name": "DANA Inc", "ticker": "DAN" }, { "asset": "nelarabine", "nct_id": "NCT03117751", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma", "arm_role": "experimental", "sponsor_raw": "St. Jude Children's Research Hospital", "company_name": null, "ticker": null }, { "asset": "nemtabrutinib", "nct_id": "NCT05624554", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-05-19", "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "nemtabrutinib", "nct_id": "NCT05947851", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-06-01", "conditions": "Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma; Lymphoma, Small Lymphocytic; CLL; SLL", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "nemtabrutinib", "nct_id": "NCT06136559", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-09-07", "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "niraparib", "nct_id": "NCT02655016", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2019-05-17", "conditions": "Ovarian Neoplasms", "arm_role": "experimental", "sponsor_raw": "Tesaro, Inc.", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT03602859", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-10-31", "conditions": "Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma", "arm_role": "experimental", "sponsor_raw": "Tesaro, Inc.", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT03651206", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Ovarian Carcinosarcoma; Endometrial Carcinosarcoma", "arm_role": "experimental", "sponsor_raw": "ARCAGY/ GINECO GROUP", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT03748641", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2021-10-08", "conditions": "Castration-Resistant Prostatic Cancer", "arm_role": "experimental", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT03768063", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-07-05", "conditions": "Cancer", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT03981796", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11-26", "conditions": "Neoplasms", "arm_role": "active_comparator", "sponsor_raw": "Tesaro, Inc.", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT04497844", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-01-07", "conditions": "Metastatic Castration-sensitive Prostate Cancer", "arm_role": "experimental", "sponsor_raw": "Janssen Research & Development, LLC", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT04915755", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-06-28", "conditions": "Neoplasms, Breast", "arm_role": "experimental", "sponsor_raw": "GlaxoSmithKline", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT05615818", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Biliary Tract Neoplasms", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT06388733", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-12", "conditions": "Glioblastoma; GBM; Brain Neoplasms, Adult, Malignant; Brain Tumor", "arm_role": "experimental", "sponsor_raw": "Ivy Brain Tumor Center", "company_name": null, "ticker": null }, { "asset": "niraparib", "nct_id": "NCT06915025", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2032-10-31", "conditions": "Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma", "arm_role": "experimental", "sponsor_raw": "Imunon", "company_name": "Imunon, Inc.", "ticker": "IMNN" }, { "asset": "obicetrapib", "nct_id": "NCT05202509", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11", "conditions": "Atherosclerotic Cardiovascular Disease", "arm_role": "experimental", "sponsor_raw": "NewAmsterdam Pharma", "company_name": "NewAmsterdam Pharma Co N.V.", "ticker": "NAMS" }, { "asset": "obicetrapib", "nct_id": "NCT07219602", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-03", "conditions": "Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)", "arm_role": "experimental", "sponsor_raw": "NewAmsterdam Pharma", "company_name": "NewAmsterdam Pharma Co N.V.", "ticker": "NAMS" }, { "asset": "oleclumab", "nct_id": "NCT05221840", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "olezarsen", "nct_id": "NCT05681351", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03", "conditions": "Severe Hypertriglyceridemia", "arm_role": "experimental", "sponsor_raw": "Ionis Pharmaceuticals, Inc.", "company_name": "IONIS PHARMACEUTICALS INC", "ticker": "IONS" }, { "asset": "olverembatinib", "nct_id": "NCT06051409", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-12-31", "conditions": "Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive", "arm_role": "experimental", "sponsor_raw": "Ascentage Pharma Group Inc.", "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL", "ticker": "AAPG" }, { "asset": "olverembatinib", "nct_id": "NCT06423911", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2025-12", "conditions": "Chronic Myeloid Leukemia; CML; CML, Chronic Phase", "arm_role": "other", "sponsor_raw": "Ascentage Pharma Group Inc.", "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL", "ticker": "AAPG" }, { "asset": "olverembatinib", "nct_id": "NCT06640361", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-03-31", "conditions": "GIST", "arm_role": "experimental", "sponsor_raw": "Ascentage Pharma Group Inc.", "company_name": "ASCENTAGE PHARMA GROUP INTERNATIONAL", "ticker": "AAPG" }, { "asset": "olvimulogene nanivacirepvec", "nct_id": "NCT05281471", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12", "conditions": "Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma", "arm_role": "experimental", "sponsor_raw": "Genelux Corporation", "company_name": "GENELUX Corp", "ticker": "GNLX" }, { "asset": "orforglipron", "nct_id": "NCT05869903", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-07-25", "conditions": "Obesity; Overweight; Overweight or Obesity", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06649045", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11", "conditions": "OSA; Overweight or Obesity", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06672549", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-02", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06672939", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-12", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06948422", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09", "conditions": "Hypertension", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06948435", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09", "conditions": "Hypertension; Overweight or Obesity", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06952530", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-09", "conditions": "Hypertension", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06972459", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06972472", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08", "conditions": "Obesity; Overweight; Type 2 Diabetes", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT06993792", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08", "conditions": "Obesity; Overweight; Type 2 Diabetes", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT07153471", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-04", "conditions": "Osteoarthritis", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT07202884", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-03", "conditions": "Urinary Incontinence,Stress", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT07223593", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-06", "conditions": "Peripheral Arterial Disease", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT07241390", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-08", "conditions": "Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT07613307", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-05", "conditions": "Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Metabolic Diseases; Endocrine System Diseases; Feeding Behavior; Behavior; Fasting; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide Receptors; Receptors, G-Protein-Coupled; Receptors, Cell Surface; Membrane Proteins; Proteins; Receptors, Peptide", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "orforglipron", "nct_id": "NCT07668336", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2030-03", "conditions": "Diabetes Mellitus, Type 2", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "paltusotine", "nct_id": "NCT07087054", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-08", "conditions": "Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor", "arm_role": "experimental", "sponsor_raw": "Crinetics Pharmaceuticals Inc.", "company_name": "Crinetics Pharmaceuticals, Inc.", "ticker": "CRNX" }, { "asset": "patidegib", "nct_id": "NCT06050122", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-08", "conditions": "Gorlin Syndrome", "arm_role": "experimental", "sponsor_raw": "Sol-Gel Technologies, Ltd.", "company_name": "Sol-Gel Technologies Ltd.", "ticker": "SLGL" }, { "asset": "pazopanib", "nct_id": "NCT03592472", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12-30", "conditions": "Renal Cell Carcinoma", "arm_role": "experimental", "sponsor_raw": "Xynomic Pharmaceuticals, Inc.", "company_name": null, "ticker": null }, { "asset": "pazopanib", "nct_id": "NCT06263231", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-12", "conditions": "Sarcoma,Soft Tissue", "arm_role": "active_comparator", "sponsor_raw": "Intensity Therapeutics, Inc.", "company_name": "INTENSITY THERAPEUTICS, INC.", "ticker": "INTS" }, { "asset": "pegaspargase", "nct_id": "NCT03020030", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11-30", "conditions": "Acute Lymphoblastic Leukemia, Pediatric", "arm_role": "experimental", "sponsor_raw": "Dana-Farber Cancer Institute", "company_name": "DANA Inc", "ticker": "DAN" }, { "asset": "pegaspargase", "nct_id": "NCT03117751", "phase": "PHASE2;PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-30", "conditions": "Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma", "arm_role": "experimental", "sponsor_raw": "St. Jude Children's Research Hospital", "company_name": null, "ticker": null }, { "asset": "pegaspargase", "nct_id": "NCT05700448", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2029-12", "conditions": "Extranodal NK/T-cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "CStone Pharmaceuticals", "company_name": null, "ticker": null }, { "asset": "pelabresib", "nct_id": "NCT06401356", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06-02", "conditions": "Hematologic Malignancy; Solid Tumor; Advanced Malignancies", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "pitolisant", "nct_id": "NCT06366464", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-07", "conditions": "Prader-Willi Syndrome", "arm_role": "experimental", "sponsor_raw": "Harmony Biosciences Management, Inc.", "company_name": "Harmony Biosciences Holdings, Inc.", "ticker": "HRMY" }, { "asset": "pitolisant", "nct_id": "NCT07219485", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2030-08", "conditions": "Prader-Willi Syndrome", "arm_role": "experimental", "sponsor_raw": "Harmony Biosciences Management, Inc.", "company_name": "Harmony Biosciences Holdings, Inc.", "ticker": "HRMY" }, { "asset": "povorcitinib", "nct_id": "NCT06113445", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-02-24", "conditions": "NonSegmental Vitiligo", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "povorcitinib", "nct_id": "NCT06113471", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-03-17", "conditions": "NonSegmental Vitiligo", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "povorcitinib", "nct_id": "NCT06212999", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-26", "conditions": "Hidradenitis Suppurativa (HS)", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "povorcitinib", "nct_id": "NCT06855498", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-02-28", "conditions": "Hidradenitis Suppurativa (HS)", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "ralinepag", "nct_id": "NCT03683186", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2026-12", "conditions": "PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseases; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Disease", "arm_role": "experimental", "sponsor_raw": "United Therapeutics", "company_name": "UNITED THERAPEUTICS Corp", "ticker": "UTHR" }, { "asset": "ravulizumab", "nct_id": "NCT05644561", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-15", "conditions": "Generalized Myasthenia Gravis; gMG", "arm_role": "experimental", "sponsor_raw": "Alexion Pharmaceuticals, Inc.", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "ravulizumab", "nct_id": "NCT07024563", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-07-12", "conditions": "IgAN; IgAVN; Immunoglobulin A Nephropathy; Immunoglobulin A Vasculitis Associated Nephritis; Henoch-schonlein Purpura Nephritis; IgA Vasculitis", "arm_role": "experimental", "sponsor_raw": "Alexion Pharmaceuticals, Inc.", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "ravulizumab", "nct_id": "NCT07596784", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-08-27", "conditions": "Generalized Myasthenia Gravis; gMG", "arm_role": "experimental", "sponsor_raw": "Alexion Pharmaceuticals, Inc.", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "recombinant human tissue kallikrein", "nct_id": "NCT05065216", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2026-12", "conditions": "Acute Stroke; Ischemic Stroke; Stroke", "arm_role": "experimental", "sponsor_raw": "DiaMedica Therapeutics Inc", "company_name": "DiaMedica Therapeutics Inc.", "ticker": "DMAC" }, { "asset": "rescue medications", "nct_id": "NCT06132958", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-01-10", "conditions": "Endometrial Cancer", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "rescue medications", "nct_id": "NCT06356311", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-04", "conditions": "Gastroesophageal Cancer", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "rescue medications", "nct_id": "NCT07216703", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-10-29", "conditions": "Cervical Cancer", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "rescue medications", "nct_id": "NCT07318558", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2033-02-25", "conditions": "Ovarian Neoplasms; Ovarian Cancer", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "resmetirom", "nct_id": "NCT03900429", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-01", "conditions": "NASH - Nonalcoholic Steatohepatitis", "arm_role": "active_comparator", "sponsor_raw": "Madrigal Pharmaceuticals, Inc.", "company_name": "MADRIGAL PHARMACEUTICALS, INC.", "ticker": "MDGL" }, { "asset": "resmetirom", "nct_id": "NCT04951219", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03", "conditions": "Non-Alcoholic Fatty Liver Disease", "arm_role": "experimental", "sponsor_raw": "Madrigal Pharmaceuticals, Inc.", "company_name": "MADRIGAL PHARMACEUTICALS, INC.", "ticker": "MDGL" }, { "asset": "resmetirom", "nct_id": "NCT05500222", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12", "conditions": "NASH; Cirrhosis, Liver", "arm_role": "active_comparator", "sponsor_raw": "Madrigal Pharmaceuticals, Inc.", "company_name": "MADRIGAL PHARMACEUTICALS, INC.", "ticker": "MDGL" }, { "asset": "retatrutide", "nct_id": "NCT05882045", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-04-16", "conditions": "Obesity; Cardiovascular Diseases", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT05929079", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-05", "conditions": "Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT06260722", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-08", "conditions": "Diabetes Mellitus, Type 2", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT06297603", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10", "conditions": "Type 2 Diabetes", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT06383390", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-02", "conditions": "Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT06662383", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12", "conditions": "Obesity", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT06859268", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-04", "conditions": "Obesity", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT07035093", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-09", "conditions": "Obesity; Overweight; Chronic Low Back Pain (CLBP)", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT07165028", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-08", "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT07232719", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "retatrutide", "nct_id": "NCT07357415", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-10", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "rezvilutamide", "nct_id": "NCT07241416", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-03", "conditions": "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)", "arm_role": "experimental", "sponsor_raw": "Jiangsu HengRui Medicine Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "rezvilutamide", "nct_id": "NCT07611110", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-02-13", "conditions": "Metastatic Castration-resistant Prostate Cancer", "arm_role": "active_comparator", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06109779", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-01-02", "conditions": "Biliary Tract Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06357533", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-12-28", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06467357", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-06-12", "conditions": "Biliary Tract Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06564844", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-06-30", "conditions": "Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06627647", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-11-18", "conditions": "Non-squamous Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06692738", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-07-01", "conditions": "Non-small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06764875", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-04-27", "conditions": "HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06868277", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-01-17", "conditions": "Carcinoma, Non-Small Cell Lung", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06921785", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-03-16", "conditions": "Hepatocellular Carcinoma", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT06989112", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-01-19", "conditions": "Endometrial Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT07221253", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-07-31", "conditions": "Biliary Tract Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rilvegostomig", "nct_id": "NCT07431281", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-08-16", "conditions": "Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "rina", "nct_id": "NCT06619236", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-02", "conditions": "Platinum-resistant Ovarian Cancer", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "rina", "nct_id": "NCT07166094", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-08", "conditions": "Endometrial Cancer; Recurrent or Progressive Endometrial Cancer", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "rina", "nct_id": "NCT07225270", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-10", "conditions": "Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "rina", "nct_id": "NCT07564141", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2029-12", "conditions": "Platinum-Sensitive Ovarian Cancer; Ovarian Cancer", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "rina", "nct_id": "NCT07604766", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2027-09", "conditions": "Platinum-resistant Ovarian Cancer", "arm_role": "experimental", "sponsor_raw": "Genmab", "company_name": "GENMAB A/S", "ticker": "GMAB" }, { "asset": "ritlecitinib", "nct_id": "NCT06072183", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-30", "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06072183", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-30", "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06072183", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-30", "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06072183", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-30", "conditions": "Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06163326", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03-31", "conditions": "Vitiligo", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06163326", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03-31", "conditions": "Vitiligo", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06873945", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-21", "conditions": "Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib", "nct_id": "NCT06873945", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-21", "conditions": "Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib higher", "nct_id": "NCT07029711", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-02", "conditions": "Severe Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib higher", "nct_id": "NCT07029828", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-06-26", "conditions": "Severe Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib lower", "nct_id": "NCT07029711", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-02", "conditions": "Severe Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "ritlecitinib lower", "nct_id": "NCT07029828", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-06-26", "conditions": "Severe Alopecia Areata", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "rosuvastatin calcium", "nct_id": "NCT03016819", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-12", "conditions": "Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma", "arm_role": "active_comparator", "sponsor_raw": "Advenchen Laboratories, LLC", "company_name": null, "ticker": null }, { "asset": "rosuvastatin calcium", "nct_id": "NCT04602754", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-05", "conditions": "Dyslipidemia Associated With Type II Diabetes Mellitus", "arm_role": "active_comparator", "sponsor_raw": "EMS", "company_name": null, "ticker": null }, { "asset": "rosuvastatin calcium", "nct_id": "NCT07216482", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-02", "conditions": "Hyperlipidemia", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "rosuvastatin calcium", "nct_id": "NCT07474649", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2028-06-01", "conditions": "Coronary Atherosclerosis; Mixed Dyslipidemia; Hypercholesterolemia", "arm_role": "experimental", "sponsor_raw": "Daiichi Sankyo", "company_name": null, "ticker": null }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT04639986", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12", "conditions": "Metastatic Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT05089734", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2023-11-29", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT05382286", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-02", "conditions": "Triple Negative Breast Cancer; PD-L1 Positive", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT05382299", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-07", "conditions": "Triple Negative Breast Cancer; PD-L1 Negative", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT05633654", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Triple Negative Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT05840211", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-04", "conditions": "Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "sacituzumab govitecan hziy", "nct_id": "NCT06486441", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-06", "conditions": "Endometrial Cancer", "arm_role": "experimental", "sponsor_raw": "Gilead Sciences", "company_name": "GILEAD SCIENCES, INC.", "ticker": "GILD" }, { "asset": "setmelanotide", "nct_id": "NCT05093634", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-12-22", "conditions": "Obesity; Genetic Obesity", "arm_role": "experimental", "sponsor_raw": "Rhythm Pharmaceuticals, Inc.", "company_name": "RHYTHM PHARMACEUTICALS, INC.", "ticker": "RYTM" }, { "asset": "setmelanotide", "nct_id": "NCT05774756", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-03-18", "conditions": "Hypothalamic Obesity", "arm_role": "experimental", "sponsor_raw": "Rhythm Pharmaceuticals, Inc.", "company_name": "RHYTHM PHARMACEUTICALS, INC.", "ticker": "RYTM" }, { "asset": "setmelanotide", "nct_id": "NCT06760546", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-03-13", "conditions": "Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia; Optic Nerve Hypoplasia; Childhood-onset Combined Pituitary Hormone Deficiency; Pituitary Stalk Interruption Syndrome", "arm_role": "experimental", "sponsor_raw": "Rhythm Pharmaceuticals, Inc.", "company_name": "RHYTHM PHARMACEUTICALS, INC.", "ticker": "RYTM" }, { "asset": "sonelokimab", "nct_id": "NCT06641076", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-02-04", "conditions": "Arthritis, Psoriatic", "arm_role": "experimental", "sponsor_raw": "MoonLake Immunotherapeutics AG", "company_name": "MoonLake Immunotherapeutics", "ticker": "MLTX" }, { "asset": "sonelokimab", "nct_id": "NCT06641089", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-01-15", "conditions": "Arthritis, Psoriatic", "arm_role": "experimental", "sponsor_raw": "MoonLake Immunotherapeutics AG", "company_name": "MoonLake Immunotherapeutics", "ticker": "MLTX" }, { "asset": "sonelokimab", "nct_id": "NCT06768671", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-28", "conditions": "Hidradenitis Suppurativa", "arm_role": "experimental", "sponsor_raw": "MoonLake Immunotherapeutics AG", "company_name": "MoonLake Immunotherapeutics", "ticker": "MLTX" }, { "asset": "sonelokimab", "nct_id": "NCT07007637", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2028-06-13", "conditions": "Hidradenitis Suppurativa", "arm_role": "experimental", "sponsor_raw": "MoonLake Immunotherapeutics AG", "company_name": "MoonLake Immunotherapeutics", "ticker": "MLTX" }, { "asset": "sonelokimab", "nct_id": "NCT07223138", "phase": "PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2028-02-04", "conditions": "Arthritis, Psoriatic", "arm_role": "experimental", "sponsor_raw": "MoonLake Immunotherapeutics AG", "company_name": "MoonLake Immunotherapeutics", "ticker": "MLTX" }, { "asset": "sotagliflozin", "nct_id": "NCT06217302", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-12", "conditions": "Diabetic Nephropathies; Kidney Failure, Chronic; Diabetes Mellitus Type 1; Heart Failure", "arm_role": "active_comparator", "sponsor_raw": "Alessandro Doria", "company_name": null, "ticker": null }, { "asset": "sotagliflozin", "nct_id": "NCT06481891", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-07", "conditions": "Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy", "arm_role": "experimental", "sponsor_raw": "Lexicon Pharmaceuticals", "company_name": "LEXICON PHARMACEUTICALS, INC.", "ticker": "LXRX" }, { "asset": "sotorasib", "nct_id": "NCT04303780", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2022-08-02", "conditions": "KRAS p, G12c Mutated /Advanced Metastatic NSCLC", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "sotorasib", "nct_id": "NCT05920356", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06-30", "conditions": "Non-Small Cell Lung Cancer (NSCLC)", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "sotorasib", "nct_id": "NCT06252649", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-09-25", "conditions": "Metastatic Colorectal Cancer", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "sotorasib", "nct_id": "NCT06497556", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-05-19", "conditions": "Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer", "arm_role": "active_comparator", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "supportive care measures", "nct_id": "NCT06170788", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-01-25", "conditions": "Non-small Cell Lung Cancer (NSCLC)", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "supportive care measures", "nct_id": "NCT06356311", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01-04", "conditions": "Gastroesophageal Cancer", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "tafasitamab", "nct_id": "NCT04680052", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2024-02-23", "conditions": "Follicular Lymphoma; Marginal Zone Lymphoma", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "tafasitamab", "nct_id": "NCT04824092", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-09-01", "conditions": "Diffuse Large B-cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "tafasitamab", "nct_id": "NCT05429268", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-03-30", "conditions": "Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Incyte Corporation", "company_name": "INCYTE CORP", "ticker": "INCY" }, { "asset": "tafasitamab", "nct_id": "NCT06521255", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-09", "conditions": "DLBCL", "arm_role": "experimental", "sponsor_raw": "Beijing InnoCare Pharma Tech Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "talazoparib", "nct_id": "NCT05059522", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-31", "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "tapinarof", "nct_id": "NCT05172726", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-10", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Organon and Co", "company_name": "Organon & Co.", "ticker": "OGN" }, { "asset": "tapinarof", "nct_id": "NCT05981118", "phase": "PHASE2;PHASE3", "status": "ENROLLING_BY_INVITATION", "primary_completion": "2026-07", "conditions": "ICD10 Code L40.9 for Psoriasis", "arm_role": "active_comparator", "sponsor_raw": "Wake Forest University Health Sciences", "company_name": null, "ticker": null }, { "asset": "tapinarof", "nct_id": "NCT07265479", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-01", "conditions": "Atopic Dermatitis", "arm_role": "experimental", "sponsor_raw": "Organon and Co", "company_name": "Organon & Co.", "ticker": "OGN" }, { "asset": "tarlatamab", "nct_id": "NCT05740566", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-01-29", "conditions": "Small Cell Lung Cancer (SCLC)", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "tarlatamab", "nct_id": "NCT06117774", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2030-04-20", "conditions": "Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "tarlatamab", "nct_id": "NCT06211036", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-05", "conditions": "Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "tarlatamab", "nct_id": "NCT07005128", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-01-04", "conditions": "Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "Amgen", "company_name": "AMGEN INC", "ticker": "AMGN" }, { "asset": "tarlatamab", "nct_id": "NCT07637513", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2037-11", "conditions": "Limited Stage Small-Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "PrECOG, LLC.", "company_name": null, "ticker": null }, { "asset": "telisotuzumab adizutecan", "nct_id": "NCT06614192", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-08", "conditions": "Metastatic Colorectal Cancer", "arm_role": "experimental", "sponsor_raw": "AbbVie", "company_name": "AbbVie Inc.", "ticker": "ABBV" }, { "asset": "telisotuzumab adizutecan", "nct_id": "NCT07005102", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2031-12", "conditions": "Non-Squamous Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AbbVie", "company_name": "AbbVie Inc.", "ticker": "ABBV" }, { "asset": "telisotuzumab adizutecan", "nct_id": "NCT07155187", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2030-09", "conditions": "Non-Small Cell Lung Cancer", "arm_role": "experimental", "sponsor_raw": "AbbVie", "company_name": "AbbVie Inc.", "ticker": "ABBV" }, { "asset": "telisotuzumab adizutecan", "nct_id": "NCT07525206", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-05", "conditions": "Colorectal Cancer", "arm_role": "experimental", "sponsor_raw": "AbbVie", "company_name": "AbbVie Inc.", "ticker": "ABBV" }, { "asset": "telitacicept", "nct_id": "NCT06456580", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-05", "conditions": "Generalized Myasthenia Gravis", "arm_role": "experimental", "sponsor_raw": "Vor Biopharma", "company_name": "Vor Biopharma Inc.", "ticker": "VOR" }, { "asset": "telitacicept", "nct_id": "NCT07249632", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12-31", "conditions": "Myasthenia Gravis, Ocular", "arm_role": "experimental", "sponsor_raw": "RemeGen Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "tezepelumab", "nct_id": "NCT06023589", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-05-31", "conditions": "Asthma", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "tezepelumab", "nct_id": "NCT06740045", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2025-03", "conditions": "Asthma; Chronic Rhinosinusitis With Nasal Polyps", "arm_role": "experimental", "sponsor_raw": "Dr. Andrew Thamboo, MD", "company_name": null, "ticker": null }, { "asset": "tezepelumab", "nct_id": "NCT07013123", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2029-08-18", "conditions": "Severe Asthma; Allergy to House Dust Mites", "arm_role": "experimental", "sponsor_raw": "University Hospital, Montpellier", "company_name": null, "ticker": null }, { "asset": "tezepelumab", "nct_id": "NCT07302516", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2028-12", "conditions": "Asthma", "arm_role": "experimental", "sponsor_raw": "Qilu Pharmaceutical Co., Ltd.", "company_name": null, "ticker": null }, { "asset": "tezepelumab", "nct_id": "NCT07363642", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-08-07", "conditions": "Severe Asthma", "arm_role": "experimental", "sponsor_raw": "AstraZeneca", "company_name": "ASTRAZENECA PLC", "ticker": "AZN" }, { "asset": "tirzepatide", "nct_id": "NCT05556512", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-10", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06075667", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-06-02", "conditions": "Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06439277", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-10", "conditions": "Obesity; Weight Gain", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06662383", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12", "conditions": "Obesity", "arm_role": "active_comparator", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06914895", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11", "conditions": "Type 1 Diabetes; Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06937086", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-04", "conditions": "Ulcerative Colitis; Obesity or Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06937099", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-05", "conditions": "Crohn's Disease; Obesity or Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT06962280", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-11", "conditions": "Type 1 Diabetes; Obesity; Overweight", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT07165028", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2030-08", "conditions": "Metabolic Dysfunction-Associated Steatotic Liver Disease", "arm_role": "experimental", "sponsor_raw": "Eli Lilly and Company", "company_name": "ELI LILLY & Co", "ticker": "LLY" }, { "asset": "tirzepatide", "nct_id": "NCT07481747", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-02-14", "conditions": "Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities", "arm_role": "experimental", "sponsor_raw": "Hudson Biotech", "company_name": null, "ticker": null }, { "asset": "tisagenlecleucel", "nct_id": "NCT04094311", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-03-31", "conditions": "B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "tisagenlecleucel", "nct_id": "NCT05888493", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-07-25", "conditions": "Follicular Lymphoma (FL)", "arm_role": "experimental", "sponsor_raw": "Novartis Pharmaceuticals", "company_name": "NOVARTIS AG", "ticker": "NVS" }, { "asset": "tocilizumab", "nct_id": "NCT04408638", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-03-31", "conditions": "Diffuse Large B-cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "tocilizumab", "nct_id": "NCT04888221", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-01-29", "conditions": "Giant Cell Arteritis; Neurovascular Disorder", "arm_role": "experimental", "sponsor_raw": "Assistance Publique - Hôpitaux de Paris", "company_name": null, "ticker": null }, { "asset": "tocilizumab", "nct_id": "NCT05171647", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-02-17", "conditions": "Non-Hodgkin Lymphoma", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "tocilizumab", "nct_id": "NCT06084936", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-08-31", "conditions": "Lymphoma", "arm_role": "experimental", "sponsor_raw": "Hoffmann-La Roche", "company_name": null, "ticker": null }, { "asset": "tocilizumab", "nct_id": "NCT07570173", "phase": "PHASE2;PHASE3", "status": "RECRUITING", "primary_completion": "2033-10-18", "conditions": "B-cell Acute Lymphoblastic Leukemia", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "tofacitinib", "nct_id": "NCT04624230", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-04-14", "conditions": "Ulcerative Colitis", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "tofacitinib", "nct_id": "NCT06020144", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-01-15", "conditions": "Rheumatoid Arthritis", "arm_role": "active_comparator", "sponsor_raw": "Hangzhou Highlightll Pharmaceutical Co., Ltd", "company_name": null, "ticker": null }, { "asset": "tradipitant", "nct_id": "NCT07446439", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-12-01", "conditions": "Nausea and Vomiting; Obesity", "arm_role": "experimental", "sponsor_raw": "Vanda Pharmaceuticals", "company_name": "Vanda Pharmaceuticals Inc.", "ticker": "VNDA" }, { "asset": "tulisokibart", "nct_id": "NCT06052059", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-08-01", "conditions": "Ulcerative Colitis", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "tulisokibart", "nct_id": "NCT06052059", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-08-01", "conditions": "Ulcerative Colitis", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "tulisokibart", "nct_id": "NCT06430801", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-10-30", "conditions": "Crohn's Disease", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "tulisokibart", "nct_id": "NCT06430801", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-10-30", "conditions": "Crohn's Disease", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "tulisokibart", "nct_id": "NCT06651281", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2037-12-17", "conditions": "Crohn Disease; Colitis, Ulcerative", "arm_role": "experimental", "sponsor_raw": "Merck Sharp & Dohme LLC", "company_name": "Merck & Co., Inc.", "ticker": "MRK" }, { "asset": "utomilumab", "nct_id": "NCT05059522", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-31", "conditions": "Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "vepdegestrant", "nct_id": "NCT05654623", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-01-31", "conditions": "Advanced Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "vepdegestrant", "nct_id": "NCT05909397", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-12-30", "conditions": "Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Pfizer", "company_name": "PFIZER INC", "ticker": "PFE" }, { "asset": "zanidatamab", "nct_id": "NCT05152147", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2026-07-31", "conditions": "Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma", "arm_role": "experimental", "sponsor_raw": "Jazz Pharmaceuticals", "company_name": "Jazz Pharmaceuticals plc", "ticker": "JAZZ" }, { "asset": "zanidatamab", "nct_id": "NCT05615818", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-06", "conditions": "Biliary Tract Neoplasms", "arm_role": "experimental", "sponsor_raw": "UNICANCER", "company_name": null, "ticker": null }, { "asset": "zanidatamab", "nct_id": "NCT06282575", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-12-01", "conditions": "Biliary Tract Cancer", "arm_role": "experimental", "sponsor_raw": "Jazz Pharmaceuticals", "company_name": "Jazz Pharmaceuticals plc", "ticker": "JAZZ" }, { "asset": "zanidatamab", "nct_id": "NCT06435429", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-04-28", "conditions": "Metastatic HER2-positive Breast Cancer", "arm_role": "experimental", "sponsor_raw": "Jazz Pharmaceuticals", "company_name": "Jazz Pharmaceuticals plc", "ticker": "JAZZ" }, { "asset": "zanubrutinib", "nct_id": "NCT03336333", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2021-05-07", "conditions": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma", "arm_role": "experimental", "sponsor_raw": "BeiGene", "company_name": null, "ticker": null }, { "asset": "zanubrutinib", "nct_id": "NCT04002297", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-03", "conditions": "Mantle Cell Lymphoma; Non-Hodgkin Lymphoma", "arm_role": "experimental", "sponsor_raw": "BeOne Medicines", "company_name": "BeOne Medicines Ltd.", "ticker": "ONC" }, { "asset": "zanubrutinib", "nct_id": "NCT04170283", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-11", "conditions": "B-cell Malignancies", "arm_role": "experimental", "sponsor_raw": "BeiGene", "company_name": null, "ticker": null }, { "asset": "zanubrutinib", "nct_id": "NCT04662255", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-01", "conditions": "Lymphoma, Mantle-Cell", "arm_role": "active_comparator", "sponsor_raw": "Loxo Oncology, Inc.", "company_name": null, "ticker": null }, { "asset": "zanubrutinib", "nct_id": "NCT05100862", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2028-07", "conditions": "Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma", "arm_role": "experimental", "sponsor_raw": "BeOne Medicines", "company_name": "BeOne Medicines Ltd.", "ticker": "ONC" }, { "asset": "zanubrutinib", "nct_id": "NCT06073821", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2032-02", "conditions": "CLL", "arm_role": "experimental", "sponsor_raw": "BeOne Medicines", "company_name": "BeOne Medicines Ltd.", "ticker": "ONC" }, { "asset": "zanubrutinib", "nct_id": "NCT06742996", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-08-31", "conditions": "Mantle Cell Lymphoma; B Cell Lymphoma", "arm_role": "experimental", "sponsor_raw": "BeOne Medicines", "company_name": "BeOne Medicines Ltd.", "ticker": "ONC" }, { "asset": "zanubrutinib", "nct_id": "NCT07277231", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-02", "conditions": "Chronic Lymphocytic Leukemia", "arm_role": "experimental", "sponsor_raw": "BeOne Medicines", "company_name": "BeOne Medicines Ltd.", "ticker": "ONC" }, { "asset": "zanubrutinib", "nct_id": "NCT07377578", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2031-05-30", "conditions": "Mantle Cell Lymphoma", "arm_role": "active_comparator", "sponsor_raw": "Guangzhou Lupeng Pharmaceutical Company LTD.", "company_name": null, "ticker": null }, { "asset": "zasocitinib", "nct_id": "NCT06323356", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2025-10-15", "conditions": "Generalized Pustular Psoriasis; Erythrodermic Psoriasis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT06550076", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2029-08-05", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT06671483", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-05-18", "conditions": "Psoriatic Arthritis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT06671496", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-05-18", "conditions": "Psoriatic Arthritis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT07250802", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2033-01-24", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT07250802", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2033-01-24", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT07250802", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2033-01-24", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT07250802", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2033-01-24", "conditions": "Plaque Psoriasis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "zasocitinib", "nct_id": "NCT07286058", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2029-12-18", "conditions": "Psoriatic Arthritis", "arm_role": "experimental", "sponsor_raw": "Takeda", "company_name": "TAKEDA PHARMACEUTICAL CO LTD", "ticker": "TAK" }, { "asset": "ziltivekimab", "nct_id": "NCT05636176", "phase": "PHASE3", "status": "ACTIVE_NOT_RECRUITING", "primary_completion": "2027-07-02", "conditions": "Heart Failure", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "ziltivekimab", "nct_id": "NCT06200207", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2026-10-01", "conditions": "Heart Failure; Systemic Inflammation", "arm_role": "active_comparator", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "ziltivekimab", "nct_id": "NCT07276282", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-09-01", "conditions": "Coronary Artery Disease; Acute Myocardial Infarction (AMI); Coronary Atherosclerosis of Native Coronary Artery", "arm_role": "experimental", "sponsor_raw": "ECRI bv", "company_name": null, "ticker": null }, { "asset": "ziltivekimab", "nct_id": "NCT07301034", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2028-11-14", "conditions": "Myocardial Infarction", "arm_role": "experimental", "sponsor_raw": "Novo Nordisk A/S", "company_name": "NOVO NORDISK A S", "ticker": "NVO" }, { "asset": "zodasiran", "nct_id": "NCT07037771", "phase": "PHASE3", "status": "RECRUITING", "primary_completion": "2027-08-20", "conditions": "Homozygous Familial Hypercholesterolemia", "arm_role": "experimental", "sponsor_raw": "Arrowhead Pharmaceuticals", "company_name": "ARROWHEAD PHARMACEUTICALS, INC.", "ticker": "ARWR" }, { "asset": "zodasiran", "nct_id": "NCT07473843", "phase": "PHASE3", "status": "NOT_YET_RECRUITING", "primary_completion": "2028-07", "conditions": "Homozygous Familial Hypercholesterolemia", "arm_role": "experimental", "sponsor_raw": "Arrowhead Pharmaceuticals", "company_name": "ARROWHEAD PHARMACEUTICALS, INC.", "ticker": "ARWR" } ]